Annovis Bio resumes Alzheimer's study delayed by Covid-19 outbreak

The company is testing its experimental therapy in patients with early-onset Alzheimer's.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.